

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jun 2026

### The effect of nigella sativa oil on serum levels of Total antioxidant capacity(TAOC) and Malondialdehyde(MDA) in patients with polycystic ovarian syndrome

#### Protocol summary

##### Study aim

Determining the effect of nigella sativa oil on serum level of Malondialdehyde(MDA) , Total antioxidant capacity(TAOC) and lipid profile in patient with polycystic ovarysyndrome.

##### Design

The study is conducted in an interventional (phase 3 clinical trial) and on 60 patients with polycystic syndrome .patients will be randomly divided into two groups of 30 using envelopes containing medicine and placebo and two blinders.the case groups will be given black seed oil at dose of 1000 mg daily for 12 weeks, and the control group will be given a placebo drug at the same dose and time

##### Settings and conduct

The study is conducted on 60 patients with polycystic syndrome referred to the obstetrics and Gynecology clinic of Alavi Hospital in ardabil.patients will be randomly divided into two groups. black seed oil will be given to the case group for 12 weeks and placebo to the control group.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria:Menstural cycle disorders,clinicalor biochemical hyperandrogenism and sonographic appearance of polycystic syndrome Exclusion criteria:Type 2 diabets,adernal hyperplasia,thyroid diseases,autoimmune diseases and hyperprolactinemia,diet and special drug use

##### Intervention groups

The case group received 12 weeks of blackseed oil with a dose of 1000 mg daily and the placebo drug control group with the same dose and time

##### Main outcome variables

Malondialdehyde(MDA),Total antioxidant capacity(TAOC),Lipid profile

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20231124060163N1**

Registration date: **2023-12-06, 1402/09/15**

Registration timing: **prospective**

Last update: **2023-12-06, 1402/09/15**

Update count: **0**

##### Registration date

2023-12-06, 1402/09/15

##### Registrant information

##### Name

Negin Panahikaleybar

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 4444 0168

##### Email address

negin.panahi69@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-12-21, 1402/09/30

##### Expected recruitment end date

2024-03-19, 1402/12/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

The effect of nigella sativa oil on serum levels of Total antioxidant capacity(TAOC) and Malondialdehyde(MDA) in patients with polycystic ovarian syndrome

## Public title

Effect of Nigella sativa oil in patients with polycystic ovary

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Oligomenorrhea or lack of ovulation polycystic ovaries based on ultrasound Androgenic hormone changes in laboratory or clinical form (the presence of hirsutism)

### Exclusion criteria:

Type 2 diabetes Thyroid disease Adrenal hyperplasia Autoimmune disease Hyperprolactinemia People with structured physical activity or scheduled exercise If three months before entering the study, they use a special diet or special drugs that may affect the results, they will be excluded from the study, such as anti-obesity drugs, induction ovulation, antidepressants, insulin sensitivity, oral contraceptives, aspirin, and anti-prostaglandin drugs If there are signs of pregnancy, they will be excluded from the study

## Age

From **18 years** old to **40 years** old

## Gender

Female

## Phase

3

## Groups that have been masked

*No information*

## Sample size

Target sample size: **60**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Using envelopes (A and B) containing medicine and placebo, they will be randomly divided into two groups. Based on the calculated sample size, 30 envelopes A and 30 envelopes B are placed in a lottery container, and then the envelopes are randomly removed from the container without replacement and the created sequence will be recorded.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

In this study, double-blind will be used so that patient and the student who provides the envelope to the patient will be blind to the content of the envelopes (intervention or placebo)

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Ardabil university of Medical sciences

##### Street address

Faculty of medicine, 1st floor, university street, 8599156189

##### City

Ardabil

##### Province

Ardabil

##### Postal code

8599156189

#### Approval date

2023-08-17, 1402/05/26

#### Ethics committee reference number

IR.ARUMS.REC.1402.128

## Health conditions studied

### 1

#### Description of health condition studied

Polycystic ovary syndrome

#### ICD-10 code

E28.2

#### ICD-10 code description

Polycystic ovarian syndrome

## Primary outcomes

### 1

#### Description

Malondialdehyde(MDA)

#### Timepoint

Before and after 12 weeks of intervention

#### Method of measurement

Determination of serum level

### 2

#### Description

Total antioxidant capacity(TAOC)

#### Timepoint

Before and after 12 weeks of intervention

#### Method of measurement

Determination of serum level

## Secondary outcomes

### 1

#### Description

Triglyceride

#### Timepoint

Before and after 12 weeks of intervention

## Method of measurement

Determination of serum level

## 2

### Description

cholesterol

### Timepoint

Before and after 12 weeks of intervention

### Method of measurement

Determination of serum level

## 3

### Description

High-density lipoprotein (HDL)

### Timepoint

Before and after 12 weeks of intervention

### Method of measurement

Determination of serum level

## 4

### Description

Low-density lipoprotein (LDL)

### Timepoint

Before and after 12 weeks of intervention

### Method of measurement

Determination of serum level

## Intervention groups

## 1

### Description

Intervention group:subjects receiving black seed oil,In this group,subjects will receive capsules containing black seed oil with a dose of1000 mg per day orally for three months.Black seed oil capsules will be provided by Barij Essans oil company(kashan).

### Category

Treatment - Drugs

## 2

### Description

Control group: subjects receiving placebo capsules,in this group ,subjects will receive capules containing placebo,which are similar to capsules containing black seed oil in terms of shape,color and side ingredients,orally daily for three months.placebo capsules will be provided from Barij Essans oil company(kashan).

### Category

Placebo

## Recruitment centers

## 1

### Recruitment center

Name of recruitment center

Alavi Ardabil Hospital

### Full name of responsible person

SHahla Farzipour

### Street address

Sport field-Alavi Hospital

### City

Ardabil

### Province

Ardabil

### Postal code

5613974156

### Phone

+98 45 3324 8888

### Fax

+98 45 3323 7821

### Email

shahla.farzipour@gmail.com

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Ardabil University of Medical Sciences

#### Full name of responsible person

SHahla farzipour

#### Street address

Sport field-Alavi Hospital

#### City

Ardabil

#### Province

Ardabil

#### Postal code

5613974156

#### Phone

+98 45 3324 8888

#### Fax

+98 45 3323 7821

#### Email

shahla.farzipour@gmail.com

### Grant name

### Grant code / Reference number

### Is the source of funding the same sponsor organization/entity?

Yes

### Title of funding source

Ardabil University of Medical Sciences

### Proportion provided by this source

80

### Public or private sector

Public

### Domestic or foreign origin

Domestic

### Category of foreign source of funding

empty

### Country of origin

### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

SHahla Farzipour

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Sport field-Alavi Hospital

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613974156

**Phone**

+98 45 3324 8888

**Email**

shahla.farzipour@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

SHahla Farzipour

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Sport field-Alavi Hospital

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613974156

**Phone**

+98 45 3324 8888

**Fax**

+98 45 3323 7821

**Email**

shahla.farzipour@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Negin Panahi kaleybar

**Position**

Resident of gynecology and obstetrics

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Sport field-Ardabil Hospital

**City**

Ardabil

**Province**

East Azarbaijan

**Postal code**

5613974156

**Phone**

+98 45 3324 8888

**Email**

Negin.panahi69@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Demographic, clinical and outcome data

**When the data will become available and for how long**

No time limit

**To whom data/document is available**

Journal if needed

**Under which criteria data/document could be used**

With permission from the university Ethics committee

**From where data/document is obtainable**

corresponding

**What processes are involved for a request to access data/document**

A written request from the relevant unit and permission from the university Ethics committee

**Comments**